Try a new search

Format these results:

Searched for:

person:ses2127

in-biosketch:true

Total Results:

306


Veterans Health Administration National TeleOncology Service

Zullig, Leah L; Raska, Whitney; McWhirter, Gina; Sherman, Scott E; Makarov, Danil; Becker, Daniel; King, Heather A; Pura, John; Jeffreys, Amy S; Danus, Susanne; Passero, Vida; Goldstein, Karen M; Kelley, Michael J
PURPOSE/UNASSIGNED:As the largest integrated health care system in the United States, the Veterans Health Administration (VA) is a leader in telehealth-delivered care. All 10 million Veterans cared for within the VA are eligible for telehealth. The VA cares for approximately 46,000 Veteran patients with newly diagnosed cancer and an estimated 400,000 prevalent cases annually. With nearly 38% of VA health care system users residing in rural areas and only 44% of rural counties having an oncologist, many Veterans lack local access to specialized cancer services. METHODS/UNASSIGNED:We describe the VA's National TeleOncology (NTO) Service. NTO was established to provide Veterans with the opportunity for specialized treatment regardless of geographical location. Designed as a hub-and-spoke model, VA oncologists from across the country can provide care to patients at spoke sites. Spoke sites are smaller and rural VA medical centers that are less able to independently provide the full range of services available at larger facilities. In addition to smaller rural spoke sites, NTO also provides subspecialized oncology care to Veterans located in larger VA medical facilities that do not have subspecialties available or that have limited capacity. RESULTS/UNASSIGNED:As of fiscal year 2021, 23 clinics are served by or engaged in planning for delivery of NTO and there are 24 physicians providing care through the NTO virtual hub. Most NTO physicians continue to provide patient care in separate traditional in-person clinics. Approximately 4,300 unique Veterans have used NTO services. Approximately half (52%) of Veterans using NTO lived in rural areas. Most of these Veterans had more than one remote visit through NTO. CONCLUSION/UNASSIGNED:NTO is a state-of-the-art model that has the potential to revolutionize the way cancer care is delivered, which should improve the experience of Veterans receiving cancer care.
PMCID:10113113
PMID: 36649579
ISSN: 2688-1535
CID: 5462132

Implementation fidelity to a behavioral diabetes prevention intervention in two New York City safety net primary care practices

Gupta, Avni; Hu, Jiyuan; Huang, Shengnan; Diaz, Laura; Gore, Radhika; Levy, Natalie; Bergman, Michael; Tanner, Michael; Sherman, Scott E; Islam, Nadia; Schwartz, Mark D
BACKGROUND:It is critical to assess implementation fidelity of evidence-based interventions and factors moderating fidelity, to understand the reasons for their success or failure. However, fidelity and fidelity moderators are seldom systematically reported. The study objective was to conduct a concurrent implementation fidelity evaluation and examine fidelity moderators of CHORD (Community Health Outreach to Reduce Diabetes), a pragmatic, cluster-randomized, controlled trial to test the impact of a Community Health Workers (CHW)-led health coaching intervention to prevent incident type 2 Diabetes Mellitus in New York (NY). METHODS:We applied the Conceptual Framework for Implementation Fidelity to assess implementation fidelity and factors moderating it across the four core intervention components: patient goal setting, education topic coaching, primary care (PC) visits, and referrals to address social determinants of health (SDH), using descriptive statistics and regression models. PC patients with prediabetes receiving care from safety-net patient-centered medical homes (PCMHs) at either, VA NY Harbor or at Bellevue Hospital (BH) were eligible to be randomized into the CHW-led CHORD intervention or usual care. Among 559 patients randomized and enrolled in the intervention group, 79.4% completed the intake survey and were included in the analytic sample for fidelity assessment. Fidelity was measured as coverage, content adherence and frequency of each core component, and the moderators assessed were implementation site and patient activation measure. RESULTS:Content adherence was high for three components with nearly 80.0% of patients setting ≥ 1 goal, having ≥ 1 PC visit and receiving ≥ 1 education session. Only 45.0% patients received ≥ 1 SDH referral. After adjusting for patient gender, language, race, ethnicity, and age, the implementation site moderated adherence to goal setting (77.4% BH vs. 87.7% VA), educational coaching (78.9% BH vs. 88.3% VA), number of successful CHW-patient encounters (6 BH vs 4 VA) and percent of patients receiving all four components (41.1% BH vs. 25.7% VA). CONCLUSIONS:The fidelity to the four CHORD intervention components differed between the two implementation sites, demonstrating the challenges in implementing complex evidence-based interventions in different settings. Our findings underscore the importance of measuring implementation fidelity in contextualizing the outcomes of randomized trials of complex multi-site behavioral interventions. TRIAL REGISTRATION:The trial was registered with ClinicalTrials.gov on 30/12/2016 and the registration number is NCT03006666 .
PMCID:10045092
PMID: 36978071
ISSN: 1471-2458
CID: 5454102

High prevalence of cardiometabolic risk factors amongst young adults in the United Arab Emirates: the UAE Healthy Future Study

Mezhal, Fatima; Oulhaj, Abderrahim; Abdulle, Abdishakur; AlJunaibi, Abdulla; Alnaeemi, Abdulla; Ahmad, Amar; Leinberger-Jabari, Andrea; Al Dhaheri, Ayesha S; AlZaabi, Eiman; Al-Maskari, Fatma; Alanouti, Fatme; Alameri, Fayza; Alsafar, Habiba; Alblooshi, Hamad; Alkaabi, Juma; Wareth, Laila Abdel; Aljaber, Mai; Kazim, Marina; Weitzman, Michael; Al-Houqani, Mohammad; Ali, Mohammad Hag; Tuzcu, E Murat; Oumeziane, Naima; El-Shahawy, Omar; Al-Rifai, Rami H; Sherman, Scott; Shah, Syed M; Alzaabi, Thekra; Loney, Tom; Almahmeed, Wael; Idaghdour, Youssef; Ahmed, Luai A; Ali, Raghib
BACKGROUND:Cardiovascular disease (CVD) is the leading cause of death in the world. In the United Arab Emirates (UAE), it accounts for 40% of mortality. CVD is caused by multiple cardiometabolic risk factors (CRFs) including obesity, dysglycemia, dyslipidemia, hypertension and central obesity. However, there are limited studies focusing on the CVD risk burden among young Emirati adults. This study investigates the burden of CRFs in a sample of young Emiratis, and estimates the distribution in relation to sociodemographic and behavioral determinants. METHODS:Data was used from the baseline data of the UAE Healthy Future Study volunteers. The study participants were aged 18 to 40 years. The study analysis was based on self-reported questionnaires, anthropometric and blood pressure measurements, as well as blood analysis. RESULTS:A total of 5167 participants were included in the analysis; 62% were males and the mean age of the sample was 25.7 years. The age-adjusted prevalence was 26.5% for obesity, 11.7% for dysglycemia, 62.7% for dyslipidemia, 22.4% for hypertension and 22.5% for central obesity. The CRFs were distributed differently when compared within social and behavioral groups. For example, obesity, dyslipidemia and central obesity in men were found higher among smokers than non-smokers (p < 0.05). And among women with lower education, all CRFs were reported significantly higher than those with higher education, except for hypertension. Most CRFs were significantly higher among men and women with positive family history of common non-communicable diseases. CONCLUSIONS:CRFs are highly prevalent in the young Emirati adults of the UAE Healthy Future Study. The difference in CRF distribution among social and behavioral groups can be taken into account to target group-specific prevention measures.
PMCID:10015775
PMID: 36922773
ISSN: 1471-2261
CID: 5448952

The Impact of the COVID-19 Pandemic on Tobacco Treatment Program Implementation at NCI-Designated Cancer Centers

Hohl, Sarah D; Shoenbill, Kimberly A; Taylor, Kathryn L; Minion, Mara; Bates-Pappas, Gleneara E; Hayes, Rashelle B; Nolan, Margaret B; Simmons, Vani N; Steinberg, Michael B; Park, Elyse R; Ashing, Kimlin; Beneventi, Diane; Cox, Lisa Sanderson; Goldstein, Adam O; King, Andrea; Kotsen, Chris; Presant, Cary A; Sherman, Scott E; Sheffer, Christine E; Warren, Graham W; Adsit, Robert T; Bird, Jennifer E; D'Angelo, Heather; Fiore, Michael C; Nguyen, Claire Van Thanh; Pauk, Danielle; Rolland, Betsy; Rigotti, Nancy A
INTRODUCTION/BACKGROUND:The COVID-19 pandemic disrupted cancer screening and treatment delivery, but COVID-19's impact on tobacco cessation treatment for cancer patients who smoke has not been widely explored. METHODS:We conducted a sequential cross-sectional analysis of data collected from 34 NCI-designated cancer centers participating in NCI's Cancer Center Cessation Initiative (C3I), across three reporting periods: one prior to COVID-19 (January-June 2019) and two during the pandemic (January-June 2020, January-June 2021). Using McNemar's Test of Homogeneity, we assessed changes in services offered and implementation activities over time. RESULTS:The proportion of centers offering remote treatment services increased each year for Quitline referrals (56%, 68%, and 91%; p=.000), telephone counseling (59%, 79%, and 94%; p=.002), and referrals to Smokefree TXT (27%, 47%, and 56%; p=.006). Centers offering video-based counseling increased from 2020 to 2021 (18% to 59%; p=.006), Fewer than 10% of centers reported laying off tobacco treatment staff. Compared to early 2020, in 2021 C3I centers reported improvements in their ability to maintain staff and clinician morale, refer to external treatment services, train providers to deliver tobacco treatment, and modify clinical workflows. DISCUSSION/CONCLUSIONS:The COVID-19 pandemic necessitated rapid transition to new telehealth program delivery of tobacco treatment for patients with cancer. C3I cancer centers adjusted rapidly to challenges presented by the pandemic, with improvements reported in staff morale and ability to train providers, refer patients to tobacco treatment, and modify clinical workflows. These factors enabled C3I centers to sustain evidence-based tobacco treatment implementation during and beyond the COVID-19 pandemic. IMPLICATIONS/CONCLUSIONS:This work describes how NCI-designated cancer centers participating in the Cancer Center Cessation Initiative (C3I) adapted to challenges to sustain evidence-based tobacco use treatment programs during the COVID-19 pandemic. This work offers a model for resilience and rapid transition to remote tobacco treatment services delivery and proposes a policy and research agenda for telehealth services as an approach to sustaining evidence-based tobacco treatment programs.
PMID: 35778237
ISSN: 1469-994x
CID: 5281522

Association Between Self-Reported Polycystic Ovary Syndrome with Chronic Diseases Among Emiratis: A Cross-Sectional Analysis from the UAE Healthy Future Study

Juber, Nirmin F.; Abdulle, Abdishakur; Aljunaibi, Abdulla; Alnaeemi, Abdulla; Ahmad, Amar; Leinberger-Jabari, Andrea; Al Dhaheri, Ayesha S.; Alzaabi, Eiman; Al-Maskari, Fatma; Alanouti, Fatme; Alsafar, Habiba; Alkaabi, Juma; Wareth, Laila Abdel; Aljaber, Mai; Kazim, Marina; Weitzman, Michael; Al-Houqani, Mohammad; Hag-Ali, Mohammed; Oumeziane, Naima; Sherman, Scott; Shah, Syed M.; Almahmeed, Wael; Idaghdour, Youssef; Loney, Tom; El-Shahawy, Omar; Ali, Raghib
Purpose: This study aimed to assess the prevalence of self-reported polycystic ovary syndrome (PCOS) among Emiratis and examine bi-directional associations of PCOS with self-reported chronic diseases, namely: diabetes, asthma, high cholesterol, and high blood pressure. Patients and Methods: A cross-sectional analysis was performed using the UAE Healthy Future Study (UAEHFS) data collected from February 2016 to April 2022 involving 1040 Emirati women aged 25"“67 years from recruitment centers in the United Arab Emirates (UAE). The bi-directional associations between self-reported PCOS and self-reported chronic diseases were evaluated by establishing temporality based on reported age-at-diagnoses. Firstly, the associations between PCOS (diagnosed at ≥25 years) and chronic diseases (diagnosed at <25 years) were examined, followed by PCOS (diagnosed at <25 years) and chronic diseases (diagnosed at ≥25 years). Finally, a Poisson regression under unadjusted and age-and-body mass index (BMI) adjusted models was performed to obtain the risk ratio (RR) and its 95% confidence interval (CI). Results: The prevalence of PCOS in this study was 25.9%. Those with asthma and high cholesterol diagnosed at <25 years had increased risks of PCOS diagnosed at ≥25 years (RR = 1.79, 95% CI: 1.17"“2.76 for asthma; and RR = 1.61, 95% CI: 1.01"“2.59 for high cholesterol), compared to those respective healthier counterparts, after adjusting for age and BMI. No significant association was observed between PCOS diagnosed at <25 years and respective chronic diseases diagnosed at ≥25 years. Conclusion: PCOS prevalence among Emirati women was high. Asthma and high cholesterol in earlier life were associated with PCOS in later life. Understanding how chronic disease conditions and PCOS are associated in bi-directional ways may improve the surveillance of chronic disease conditions among women with PCOS and may also contribute to more targeted PCOS prevention strategies.
SCOPUS:85148649993
ISSN: 1179-1411
CID: 5445752

Association between pediatric asthma and adult polycystic ovarian syndrome (PCOS): a cross-sectional analysis of the UAE healthy future Study (UAEHFS)

Juber, Nirmin F; Abdulle, Abdishakur; AlJunaibi, Abdulla; AlNaeemi, Abdulla; Ahmad, Amar; Leinberger-Jabari, Andrea; Al Dhaheri, Ayesha S; AlZaabi, Eiman; Mezhal, Fatima; Al-Maskari, Fatma; Alanouti, Fatme; Alsafar, Habiba; Alkaabi, Juma; Wareth, Laila Abdel; Aljaber, Mai; Kazim, Marina; Weitzman, Michael; Al-Houqani, Mohammed; Hag-Ali, Mohammed; Oumeziane, Naima; El-Shahawy, Omar; Sherman, Scott; Shah, Syed M; Loney, Tom; Almahmeed, Wael; Idaghdour, Youssef; Ali, Raghib
INTRODUCTION/UNASSIGNED:Asthma and polycystic ovarian syndrome (PCOS) are linked in several possible ways. To date, there has been no study evaluating whether pediatric asthma is an independent risk factor for adult PCOS. Our study aimed to examine the association between pediatric asthma (diagnosed at 0-19 years) and adult PCOS (diagnosed at ≥20 years). We further assessed whether the aforementioned association differed in two phenotypes of adult PCOS which were diagnosed at 20-25 years (young adult PCOS), and at >25 years (older adult PCOS). We also evaluated whether the age of asthma diagnosis (0-10 vs 11-19 years) modified the association between pediatric asthma and adult PCOS. MATERIAL AND METHODS/UNASSIGNED:This is a retrospective cross-sectional analysis using the United Arab Emirates Healthy Future Study (UAEHFS) collected from February 2016 to April 2022 involving 1334 Emirati females aged 18-49 years. We fitted a Poisson regression model to estimate the risk ratio (RR) and its 95% confidence interval (95% CI) to assess the association between pediatric asthma and adult PCOS adjusting for age, urbanicity at birth, and parental smoking at birth. RESULTS/UNASSIGNED:After adjusting for confounding factors and comparing to non-asthmatic counterparts, we found that females with pediatric asthma had a statistically significant association with adult PCOS diagnosed at ≥20 years (RR=1.56, 95% CI: 1.02-2.41), with a stronger magnitude of the association found in the older adult PCOS phenotype diagnosed at >25 years (RR=2.06, 95% CI: 1.16-3.65). Further, we also found females reported thinner childhood body size had a two-fold to three-fold increased risk of adult PCOS diagnosed at ≥20 years in main analysis and stratified analyses by age of asthma and PCOS diagnoses (RR=2.06, 95% CI: 1.08-3.93 in main analysis; RR=2.74, 95% CI: 1.22-6.15 among those diagnosed with PCOS > 25 years; and RR=3.50, 95% CI: 1.38-8.43 among those diagnosed with asthma at 11-19 years). CONCLUSIONS/UNASSIGNED:Pediatric asthma was found to be an independent risk factor for adult PCOS. More targeted surveillance for those at risk of adult PCOS among pediatric asthmatics may prevent or delay PCOS in this at-risk group. Future studies with robust longitudinal designs aimed to elucidate the exact mechanism between pediatric asthma and PCOS are warranted.
PMCID:10246854
PMID: 37293507
ISSN: 1664-2392
CID: 5533592

Comparing mental and physical health of U.S. veterans by VA healthcare use: implications for generalizability of research in the VA electronic health records

Fink, David S; Stohl, Malka; Mannes, Zachary L; Shmulewitz, Dvora; Wall, Melanie; Gutkind, Sarah; Olfson, Mark; Gradus, Jaimie; Keyhani, Salomeh; Maynard, Charles; Keyes, Katherine M; Sherman, Scott; Martins, Silvia; Saxon, Andrew J; Hasin, Deborah S
OBJECTIVE:The Department of Veterans Affairs' (VA) electronic health records (EHR) offer a rich source of big data to study medical and health care questions, but patient eligibility and preferences may limit generalizability of findings. We therefore examined the representativeness of VA veterans by comparing veterans using VA healthcare services to those who do not. METHODS:We analyzed data on 3051 veteran participants age ≥ 18 years in the 2019 National Health Interview Survey. Weighted logistic regression was used to model participant characteristics, health conditions, pain, and self-reported health by past year VA healthcare use and generate predicted marginal prevalences, which were used to calculate Cohen's d of group differences in absolute risk by past-year VA healthcare use. RESULTS:Among veterans, 30.4% had past-year VA healthcare use. Veterans with lower income and members of racial/ethnic minority groups were more likely to report past-year VA healthcare use. Health conditions overrepresented in past-year VA healthcare users included chronic medical conditions (80.6% vs. 69.4%, d = 0.36), pain (78.9% vs. 65.9%; d = 0.35), mental distress (11.6% vs. 5.9%; d = 0.47), anxiety (10.8% vs. 4.1%; d = 0.67), and fair/poor self-reported health (27.9% vs. 18.0%; d = 0.40). CONCLUSIONS:Heterogeneity in veteran sociodemographic and health characteristics was observed by past-year VA healthcare use. Researchers working with VA EHR data should consider how the patient selection process may relate to the exposures and outcomes under study. Statistical reweighting may be needed to generalize risk estimates from the VA EHR data to the overall veteran population.
PMCID:9733218
PMID: 36494829
ISSN: 1472-6963
CID: 5414552

Use of patient portals to support recruitment into clinical trials and health research studies: results from studies using MyChart at one academic institution

Sherman, Scott E; Langford, Aisha T; Chodosh, Joshua; Hampp, Carina; Trachtman, Howard
Electronic health records (EHRs) are often used for recruitment into research studies, as they efficiently facilitate targeted outreach. While studies increasingly are reaching out to potential participants through the EHR patient portal, there is little available information about which approaches are most effective. We surveyed all investigators at one academic medical center who had used the Epic MyChart patient portal for recruitment. We found that messages were typically adapted for a large group, but not tailored further for individual subgroups. The vast majority of studies sent a message only once. Recruitment costs were modest, averaging $431/study. The results show some promise for recruiting through the patient portal but also identified ways in which messages could be optimized.
PMCID:9614350
PMID: 36325306
ISSN: 2574-2531
CID: 5358682

Youth E-Cigarette Use and Functionally Important Respiratory Symptoms: The Population Assessment of Tobacco and Health (PATH) Study Waves 3 and 4

Stevens, Elizabeth R; Xu, Shu; Niaura, Raymond; Cleland, Charles M; Sherman, Scott E; Mai, Andi; Karey, Emma; Jiang, Nan
Respiratory effects of e-cigarette use among youth are not fully understood. This study investigated the longitudinal association between e-cigarette use and a validated index of functionally important respiratory symptoms among US youth. Data from Waves 3-4 of the Population Assessment of Tobacco and Health Study were analyzed. The sample included youth (aged 12-17) without asthma at baseline (Wave 3), who completed a follow-up survey (Wave 4), and were not missing data for analytic variables (n = 3899). Exposure was e-cigarette use status (never, former, or current) at baseline. The outcome was a respiratory symptom index based on responses for seven wheezing items at Wave 4. An index of ≥2 was defined as having functionally important respiratory symptoms. Lagged logistic regression models examined the association between baseline e-cigarette use and functionally important respiratory symptoms at follow-up by combustible tobacco use status (never or ever), and controlling for baseline covariates. At baseline, 13.7% of participants reported former e-cigarette use, and 4.3% reported current use. Baseline e-cigarette use did not increase the odds of having functionally important respiratory symptoms at follow-up regardless of combustible tobacco use status. Future research on larger populations of e-cigarette users with longer follow-up periods will improve our understanding of the respiratory risks associated with e-cigarette use among youth.
PMCID:9690418
PMID: 36430043
ISSN: 1660-4601
CID: 5382882

Metabolic Syndrome in Fasting and Non-Fasting Participants: The UAE Healthy Future Study

Mezhal, Fatima; Ahmad, Amar; Abdulle, Abdishakur; Leinberger-Jabari, Andrea; Oulhaj, Abderrahim; AlJunaibi, Abdulla; Alnaeemi, Abdulla; Al Dhaheri, Ayesha S; AlZaabi, Eiman; Al-Maskari, Fatma; AlAnouti, Fatme; Alsafar, Habiba; Alkaabi, Juma; Wareth, Laila Abdel; Aljaber, Mai; Kazim, Marina; Alblooshi, Manal; Al-Houqani, Mohammad; Hag Ali, Mohammad; Oumeziane, Naima; El-Shahawy, Omar; Al-Rifai, Rami H; Sherman, Scott; Shah, Syed M; Loney, Tom; Almahmeed, Wael; Idaghdour, Youssef; Ahmed, Luai A; Ali, Raghib
INTRODUCTION/BACKGROUND:Metabolic syndrome (MetS) is a multiplex of risk factors that predispose people to the development of diabetes and cardiovascular disease (CVD), two of the major non-communicable diseases that contribute to mortality in the United Arab Emirates (UAE). MetS guidelines require the testing of fasting samples, but there are evidence-based suggestions that non-fasting samples are also reliable for CVD-related screening measures. In this study, we aimed to estimate MetS and its components in a sample of young Emiratis using HbA1c as another glycemic marker. We also aimed to estimate the associations of some known CVD risk factors with MetS in our population. METHODS:The study was based on a cross-sectional analysis of baseline data of 5161 participants from the UAE Healthy Future Study (UAEHFS). MetS was identified using the NCEP ATP III criteria, with the addition of HbA1c as another glycemic indicator. Fasting blood glucose (FBG) and HbA1c were used either individually or combined to identify the glycemic component of MetS, based on the fasting status. Multivariate regression analysis was used to test for associations of selected social and behavioral factors with MetS. RESULTS:&gt; 0.05). Age, increased body mass index (BMI), and family history of any metabolic abnormality and/or heart disease were consistently strongly associated with MetS. CONCLUSION/CONCLUSIONS:MetS is highly prevalent in our sample of young Emirati adults. Our data showed that HbA1c may be an acceptable tool to test for the glycemic component of MetS in non-fasting samples. We found that the most relevant risk factors for predicting the prevalence of MetS were age, BMI, and family history.
PMID: 36360639
ISSN: 1660-4601
CID: 5357562